Actualizar mis citas con la selección
Presentar
resultados
Douros A, Lix LM, Fralick M, Shah BR, Ronksley PE, Tremblay E, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ernst P, Filion KB, for the Canadian Network of Observational Drug Effect Studies (CNODES) Investigators.
Sodium–glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis A multicenter cohort study.
Ann Intern Med 2020:28 de julio. [Ref.ID 103685]
Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P.
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
BMJ 2020;369:29 de abril. [Ref.ID 103626]
Pasternak B, Ueda P, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveern K, Jonasson C, Wintzell V, Melbye M, Svanström H.
Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
BMJ 2019;366:29 de agosto. [Ref.ID 103243]
Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]
Actualizar mis citas con la selección